{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:00:38Z","timestamp":1780776038131,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"Amylin Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004323","name":"Amylin Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ahj.2026.107475","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:55:42Z","timestamp":1778108142000},"page":"107475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL"],"prefix":"10.1016","volume":"299","author":[{"given":"Veraprapas","family":"Kittipibul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svati H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ahj.2026.107475_bib0001","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"10.1016\/j.ahj.2026.107475_bib0002","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ahj.2026.107475_bib0003","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1161\/CIRCULATIONAHA.118.036811","article-title":"Effects of once-weekly exenatide on clinical outcomes in patients with preexisting cardiovascular disease","volume":"138","author":"Mentz","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahj.2026.107475_bib0004","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2337\/dc15-1760","article-title":"Natriuretic peptide and high-sensitivity troponin for cardiovascular risk prediction in diabetes: the atherosclerosis risk in communities (ARIC) study","volume":"39","author":"Gori","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ahj.2026.107475_bib0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/CIRCULATIONAHA.121.057852","article-title":"Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial","volume":"145","author":"Berg","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107475_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ahj.2015.12.009","article-title":"Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial","volume":"174","author":"Holman","year":"2016","journal-title":"Am Heart J"},{"issue":"9","key":"10.1016\/j.ahj.2026.107475_bib0007","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ahj.2026.107475_bib0008","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.amjcard.2011.05.033","article-title":"Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals","volume":"108","author":"Cheng","year":"2011","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2026.107475_bib0009","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jacc.2024.11.004","article-title":"Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: look AHEAD cardiac biomarker ancillary study","volume":"85","author":"Patel","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2026.107475_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12933-019-0857-6","article-title":"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial","volume":"18","author":"Bizino","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.ahj.2026.107475_bib0011","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.2337\/dc18-0109","article-title":"Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE trial","volume":"41","author":"Jarolim","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ahj.2026.107475_bib0012","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study","volume":"33","author":"Woo","year":"2013","journal-title":"Arter Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.ahj.2026.107475_bib0013","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12933-022-01482-z","article-title":"Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial","volume":"21","author":"Stultiens","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.ahj.2026.107475_bib0014","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12933-022-01616-3","article-title":"Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study","volume":"21","author":"Sabbatinelli","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ahj.2026.107475_bib0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijcard.2022.03.049","article-title":"Serial measurement of B-type natriuretic peptide and future cardiovascular events in patients with type 2 diabetes mellitus without known cardiovascular disease","volume":"356","author":"Ikeda","year":"2022","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2026.107475_bib0016","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/jamacardio.2023.0019","article-title":"Association of cardiac biomarkers with major adverse cardiovascular events in high-risk patients with diabetes: a secondary analysis of the DECLARE-TIMI 58 trial","volume":"8","author":"Zelniker","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2026.107475_bib0017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program","volume":"84","author":"Petrie","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326001377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326001377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:52:13Z","timestamp":1780775533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326001377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"alternative-id":["S0002870326001377"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107475","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107475"}}